Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.

TitleDysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.
Publication TypeJournal Article
Year of Publication2016
AuthorsPark, H-J, Lee, K-W, Park, ES, Oh, S, Yan, R, Zhang, J, Beach, TG, Adler, CH, Voronkov, M, Braithwaite, SP, Stock, JB, M Mouradian, M
JournalAnn Clin Transl Neurol
Volume3
Issue10
Pagination769-780
Date Published2016 10
ISSN2328-9503
Abstract

<p><b>OBJECTIVE: </b>Protein phosphatase 2A (PP2A) is a heterotrimeric holoenzyme composed of a catalytic C subunit, a structural A subunit, and one of several regulatory B subunits that confer substrate specificity. The assembly and activity of PP2A are regulated by reversible methylation of the C subunit. -Synuclein, which aggregates in Parkinson disease (PD) and dementia with Lewy bodies (DLB), is phosphorylated at Ser, and PP2A containing a B55 subunit is a major phospho-Ser phosphatase. The objective of this study was to investigate PP2A in -synucleinopathies.</p><p><b>METHODS: </b>We compared the state of PP2A methylation, as well as the expression of its methylating enzyme, leucine carboxyl methyltransferase (LCMT-1), and demethylating enzyme, protein phosphatase methylesterase (PME-1), in postmortem brains from PD and DLB cases as well as age-matched Controls. Immunohistochemical studies and quantitative image analysis were employed.</p><p><b>RESULTS: </b>LCMT-1 was significantly reduced in the substantia nigra (SN) and frontal cortex in both PD and DLB. PME-1, on the other hand, was elevated in the PD SN. In concert with these changes, the ratio of methylated PP2A to demethylated PP2A was markedly decreased in PD and DLB brains in both SN and frontal cortex. No changes in total PP2A or total B55 subunit were detected.</p><p><b>INTERPRETATION: </b>These findings support the hypothesis that PP2A dysregulation in -synucleinopathies may contribute to the accumulation of hyperphosphorylated -synuclein and to the disease process, raising the possibility that pharmacological means to enhance PP2A phosphatase activity may be a useful disease-modifying therapeutic approach.</p>

DOI10.1002/acn3.337
Alternate JournalAnn Clin Transl Neurol
PubMed ID27752512
PubMed Central IDPMC5048387
Grant ListR01 NS101134 / NS / NINDS NIH HHS / United States
U24 NS072026 / NS / NINDS NIH HHS / United States
P30 AG019610 / AG / NIA NIH HHS / United States
R01 NS073994 / NS / NINDS NIH HHS / United States
R01 AT006868 / AT / NCCIH NIH HHS / United States